ArticleCancer discovery2021
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Abstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.Nature cancer · 2026Trial
- A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.Cancer immunology research · 2026Trial
- Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer.Cancer immunology research · 2026Article
- Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastases.bioRxiv : the preprint server for biology · 2026Article
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Spatiotemporal multi-omics reveals lineage, spatial and functional heterogeneity of tumor-associated macrophages and therapeutic vulnerabilities in the tumor microenvironment.NPJ precision oncology · 2026Review
- Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway.Molecular cancer therapeutics · 2026Article
- Spatially resolved transcriptomic and proteomic profiling reveals cell interaction programs that predict Barrett's esophagus progression.bioRxiv : the preprint server for biology · 2026Article
- Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions.Signal transduction and targeted therapy · 2026Review
- Article
- Article
- Tumor-immune trajectory context connects static tissue architecture to clinical outcomes.bioRxiv : the preprint server for biology · 2026Article
- High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma.Cancer research · 2026Article
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
- Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer.Cell reports. Medicine · 2026Article
- Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.Experimental hematology & oncology · 2026Review
- ImmunoPheno: A Computational Framework for Data-Driven Design and Analysis of Immunophenotyping Experiments.bioRxiv : the preprint server for biology · 2026Article
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.Nature communications · 2026Article
- Investigation of aBMC cancer · 2026Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Shannon M Liudahl *Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-8587-8204
Courtney B Betts *Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Shamilene Sivagnanam *Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Vicente Morales-OyarvideDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Annacarolina da SilvaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0067-0288
Chen YuanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0708-9648
Samuel HwangDepartment of Pathology, Oregon Health & Science University, Portland, Oregon.
Alison Grossblatt-WaitKnight Cancer Institute, Oregon Health & Science University, Portland, OR.
Kenna R LeisDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
William LarsonDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Meghan B LavoieDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Padraic RobinsonDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Andressa Dias CostaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sara A VäyrynenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Thomas E ClancyDepartment of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Douglas A RubinsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5337-5231
Jason LinkBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.
Dove KeithBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-6104-3264
Wesley HortonDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon.
Margaret A TemperoHelen Diller Family Comprehensive Cancer Center and Department of Medicine, University of California, San Francisco, California.ORCID 0000-0002-2777-9208
Robert H VonderheideAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-7252-954X
Elizabeth M JaffeeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-3841-6549
Brett SheppardBrenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon.
Jeremy GoecksComputational Biology Program, Oregon Health & Science University, Portland, Oregon.
Rosalie C SearsKnight Cancer Institute, Oregon Health & Science University, Portland, OR.
Byung S ParkKnight Cancer Institute, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-3516-7516
Motomi MoriKnight Cancer Institute, Oregon Health & Science University, Portland, OR.
Jonathan A Nowak *Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Brian M Wolpin *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lisa M Coussens *Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon. coussenl@ohsu.edu.ORCID 0000-0003-2389-1865
Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MTransforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2021 to 2025
$12.7MUnderstanding the Impact of Microscale and Nanoscale Heterogeneity and ResistanceU54CA209988 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GRAY, JOE W. · 2017 to 2021
$10.3MOmic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DEMIR, EMEK, MILLS, GORDON B. · 2018 to 2023
$9.7MCirculating Biomarker Consortium for Pancreatic Cancer Early DetectionU01CA210171 · NCI · DANA-FARBER CANCER INST · PI Michael H. Rosenthal, Brian Matthew Wolpin · 2016 to 2026
$8.7MTargeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7MHydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2MTherapeutic Targeting of Macrophage PI3Kgamma in HNSCCR01CA226909 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kathryn Ann Gold, Judith A VARNER · 2018 to 2026
$3.9MA Federated Galaxy for user-friendly large-scale cancer genomics researchU24CA231877 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2022
$3.9MComparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9MThe Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0MNCATS NIH HHS UL1 TR002369NCI NIH HHS P01 CA247886NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228NCI NIH HHS R01 CA197296NCI NIH HHS R01 CA223150NCI NIH HHS R01 CA226909NCI NIH HHS U01 CA210171NCI NIH HHS U01 CA224012NCI NIH HHS U24 CA231877NCI NIH HHS U2C CA233280NCI NIH HHS U54 CA209988NICHD NIH HHS R21 HD099367
Abstract
Immunotherapies targeting aspects of T cell functionality are efficacious in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) remains refractory to these treatments. Deeper understanding of the PDAC immune ecosystem is needed to identify additional therapeutic targets and predictive biomarkers for therapeutic response and resistance monitoring. To address these needs, we quantitatively evaluated leukocyte contexture in 135 human PDACs at single-cell resolution by profiling density and spatial distribution of myeloid and lymphoid cells within histopathologically defined regions of surgical resections from treatment-naive and presurgically (neoadjuvant)-treated patients and biopsy specimens from metastatic PDAC. Resultant data establish an immune atlas of PDAC heterogeneity, identify leukocyte features correlating with clinical outcomes, and, through an
Indexed as
Tumor MicroenvironmentCarcinoma, Pancreatic DuctalHumansImmunotherapyLeukocytesPancreatic Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.